Join our daily newsletter At The Bell to receive exclusive market insights
- Amplia Therapeutics (ATX) recruits and doses the first patient in cohort three of its ongoing ACCENT trial for pancreatic cancer
- Under the third cohort, patients will receive an increased dosage of ATX’s AMP945 product, following the safe and well-tolerated assessment of dosage in cohort two
- ATX CEO and Managing Director Chris Burns says it is pleasing to move “rapidly” onto cohort three in a bid to progress to phase two of the trial
- The ACCENT trial is a two-staged open-label study of the pharmacokinetics, safety and efficacy of AMP945 in combination with chemotherapy in pancreatic cancer patients
- Shares in ATX are up 5.88 per cent to nine cents at 11:29 am AEST
Amplia Therapeutics (ATX) has recruited and dosed the first patient in cohort three of its ongoing ACCENT trial in pancreatic cancer.
Under the third cohort, three patients will receive an increased dosage of ATX’s AMP945 product, following the safe and well-tolerated assessment of dosage in cohort two
Through the ACCENT trial, AMP945 is dosed orally, by means of a capsule, in the lead-up to and between standardised weekly dosing of gemcitabine and nab-paclitaxel chemotherapy.
Amplia CEO and Managing Director Chris Burns said it was pleasing to progress to cohort three in the trial
“We are very pleased with the recent progress in the ACCENT trial, and moving rapidly to cohort three is the next step in identifying a safe and effective dose to take forward to the phase two stage of the trial,” Dr Burns said.
“We are extremely grateful to the clinical trial sites for their hard work in progressing the trial so quickly and to the patients and their loved ones for agreeing to take part in this trial.”
Amplia’s ACCENT trial is a two-staged open-label study of the pharmacokinetics, safety and efficacy of AMP945 in combination with chemotherapy in pancreatic cancer patients.
Shares in ATX were up 5.88 per cent to nine cents at 11:29 am AEST.
